These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 28978002)
1. Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. Li Y; Chen R; Bowden M; Mo F; Lin YY; Gleave M; Collins C; Dong X Oncotarget; 2017 Sep; 8(40):66878-66888. PubMed ID: 28978002 [TBL] [Abstract][Full Text] [Related]
2. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064 [TBL] [Abstract][Full Text] [Related]
3. SRRM4 gene expression correlates with neuroendocrine prostate cancer. Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992 [TBL] [Abstract][Full Text] [Related]
4. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347 [TBL] [Abstract][Full Text] [Related]
5. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network. Lee AR; Gan Y; Tang Y; Dong X EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395 [TBL] [Abstract][Full Text] [Related]
6. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer. Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466 [TBL] [Abstract][Full Text] [Related]
7. Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer. Gan Y; Li Y; Long Z; Lee AR; Xie N; Lovnicki JM; Tang Y; Chen X; Huang J; Dong X EBioMedicine; 2018 May; 31():267-275. PubMed ID: 29759485 [TBL] [Abstract][Full Text] [Related]
8. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054 [TBL] [Abstract][Full Text] [Related]
9. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194 [TBL] [Abstract][Full Text] [Related]
10. Targeting RET Kinase in Neuroendocrine Prostate Cancer. VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304 [TBL] [Abstract][Full Text] [Related]
11. Molecular model for neuroendocrine prostate cancer progression. Chen R; Dong X; Gleave M BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310 [TBL] [Abstract][Full Text] [Related]
12. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708 [TBL] [Abstract][Full Text] [Related]
13. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y Cells; 2020 Jun; 9(6):. PubMed ID: 32512818 [TBL] [Abstract][Full Text] [Related]
14. Smoothened loss is a characteristic of neuroendocrine prostate cancer. Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576 [TBL] [Abstract][Full Text] [Related]
15. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201 [TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594 [TBL] [Abstract][Full Text] [Related]
18. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368 [TBL] [Abstract][Full Text] [Related]
19. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network. Lee AR; Che N; Lovnicki JM; Dong X Front Oncol; 2018; 8():93. PubMed ID: 29666783 [TBL] [Abstract][Full Text] [Related]